Data from the AdisInsight database for January to July 2024 reveal that the majority of clinical trials were discontinued or suspended due to strategic decisions made by the sponsoring company or organization, with a total of 226 trials affected. This was the leading reason for trial cessation, followed by other factors such as failure to demonstrate efficacy or safety (65 trials), regulatory decisions (37 trials), and interim analysis findings (30 trials). In some cases, interim analyses indicated potential harm to participants or the futility of the treatment, prompting early termination of the trials. Additionally, financial constraints contributed to the discontinuation of 27 trials, with factors such as inadequate funding, exceeding clinical trial budgets, or non-medical costs (e.g., travel and lodging expenses) impacting the trial's viability.